BioCryst Pharmaceuticals CEO Jon Stonehouse's 2018 pay rises 6% to $4.2M
BioCryst Pharmaceuticals reports 2018 executive compensation
By ExecPay News
Published: April 17, 2019
BioCryst Pharmaceuticals reported fiscal year 2018 executive compensation information on April 17, 2019.
In 2018, five executives at BioCryst Pharmaceuticals received on average a compensation package of $2.3M, a 10% increase compared to previous year.
Average pay of disclosed executives at BioCryst Pharmaceuticals
Jon P. Stonehouse, Chief Executive Officer, received $4.2M in total, which increased by 6% compared to 2017. 79% of Stonehouse's compensation, or $3.3M, was in option awards. Stonehouse also received $325K in non-equity incentive plan, $550K in salary, as well as $15K in other compensation.
For fiscal year 2018, the median employee pay was $205,224 at BioCryst Pharmaceuticals. Therefore, the ratio of Jon P. Stonehouse's pay to the median employee pay was 20 to one.
William P. Sheridan, Chief Medical Officer, received a compensation package of $2.3M, which increased by 30% compared to previous year. 69% of the compensation package, or $1.6M, was in option awards.
Thomas R. Staab II, Chief Financial Officer, earned $1.8M in 2018, a 4% increase compared to previous year.
Yarlagadda S. Babu, Senior Vice President of Drug Discovery, received $1.8M in 2018, which increases by 7% compared to 2017.
Lynne M. Powell, Senior Vice President and Chief Commercial Officer, earned $1.5M in 2018, a 3% increase compared to previous year.
Related executives
Jon Stonehouse
BioCryst Pharmaceuticals
Chief Executive Officer
Thomas Staab
BioCryst Pharmaceuticals
Chief Financial Officer
Yarlagadda Babu
BioCryst Pharmaceuticals
Chief Discovery Officer
William Sheridan
BioCryst Pharmaceuticals
Chief Medical Officer
Lynne Powell
BioCryst Pharmaceuticals
Senior Vice President and Chief Commercial Officer
You may also like
Source: SEC filing on April 17, 2019.